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Abstract
Background: It is important that planned randomised trials are justified and placed in the context of the available
evidence. The SPIRIT guidelines for reporting clinical trial protocols recommend that a recent and relevant systematic
review should be included. The aim of this study was to assess the use of the existing evidence in order to justify
trial conduct.
Methods: Protocols of randomised trials published over a 1-month period (December 2015) indexed in PubMed were
obtained. Data on trial characteristics relating to location, design, funding, conflict of interest and type of evidence
included for trial justification was extracted in duplicate and independently by two investigators. The frequency of
citation of previous research including relevant systematic reviews and randomised trials was assessed.
Results: Overall, 101 protocols for RCTs were identified. Most proposed trials were parallel-group (n = 74; 73.3%).
Reference to an earlier systematic review with additional randomised trials was found in 9.9% (n = 10) of protocols and
without additional trials in 30.7% (n = 31), while reference was made to randomised trials in isolation in 21.8% (n = 22).
Explicit justification for the proposed randomised trial on the basis of being the first to address the research question
was made in 17.8% (n = 18) of protocols. A randomised controlled trial was not cited in 10.9% (95% CI: 5.6, 18.7) (n = 11),
while in 8.9% (95% CI: 4.2, 16.2) (n = 9) of the protocols a systematic review was cited but did not inform trial design.
Conclusions: A relatively high percentage of protocols of randomised trials involves prior citation of randomised trials,
systematic reviews or both. However, improvements are required to ensure that it is explicit that clinical trials are
justified and shaped by contemporary best evidence.
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Background
The onus on clear research reporting and indeed optimal
yield from randomised trials has been highlighted increas-
ingly in recent years with much research now accepted as
being suboptimal with ensuing financial and systemic
waste [1]. Among the more pressing shortcomings are
failure to consider questions of relevance to clinicians and
patients, inappropriate design and methods, publication
bias, and biased and incomplete reporting [2].
Accepted prerequisites for randomised trials are the
existence of genuine uncertainty concerning the relative
merits of competing interventions and appropriate
design to permit meaningful answers [3]. An appreci-
ation of the existence of previous research is therefore
necessary to avoid unnecessary duplication, and due
consideration of the evidence base is important in
informing appropriate design and methodology. Not-
withstanding this, replication of previous studies may be
justified in confirming previous results or in an effort to
assess the generalizability of novel findings [4].
It is accepted that relevant research, including system-
atic reviews where they exist and randomised trials,
should be cited in the introduction section of reports of
randomised controlled trials (RCTs) [3]. There are also
growing concerns in relation to publication bias and
selective outcome reporting in biomedical journals [5, 6].
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Consequently, in recent years there has been an increasing
drive to publish research protocols both to prevent un-
wanted duplication and to mitigate the risk of reporting
bias [7]. The Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) guidelines [7] aim to
improve the reporting and quality of clinical trial proto-
cols and incorporate a checklist of recommended items to
include in the trial protocol [7]. Within the SPIRIT guide-
lines, citation of prior research in the introduction section
and justification of randomised trials on the basis of gaps
in the underlying evidence base are advocated [7]. The
SPIRIT checklist strongly recommends placing: “The trial
in the context of available evidence, it is strongly
recommended that an up-to-date systematic review of
relevant studies be summarised and cited in the protocol.”
Previous research has addressed the issue of recognition
of prior studies in stimulating or informing further re-
search [8–10]. Robinson and Goodman [11] in an analysis
of RCTs contributing to meta-analyses identified that less
than one quarter of relevant trials had been cited. Simi-
larly, Clarke and Hopewell [10] in a survey of five leading
medical journals reported sparse referencing of systematic
reviews either in the introduction or discussion sections.
Consequently, randomised trial reports may routinely fail
to place research findings in appropriate context poten-
tially hampering the end user’s ability to reach balanced,
informed decisions about important healthcare interven-
tions. Failure to consider the available and latest evidence
may jeopardize the justification for new randomised re-
search on ethical grounds.
To our knowledge no studies exist assessing the justifica-
tion for randomised trials based on the available evidence at
the protocol stage and in accordance with SPIRIT. The aim
of this meta-epidemiological study was to assess the extent
to which published protocols of randomised trials adhere to
SPIRIT and include an updated systematic review to inform
the trial design in the background or rationale sections.
Methods
Sample
All published protocols of planned randomised con-
trolled trials (RCTs) were identified over a 1-month
period (December 2015) indexed in PubMed based on a
defined search strategy (Table 1).
Data extraction
Titles and abstracts were screened by one author (NP) in
order to select all eligible publications. The selected cita-
tions were entered in Endnote reference management
software and the corresponding full texts were retrieved
for further evaluation. The criteria for defining a report as
a “randomised controlled trial protocol” were as follows:
– Document describing the objectives, design,
methodology, statistical considerations, and
organisation of a clinical trial including justification
and rationale for the trial.
– Cochrane definition of a trial as randomised: “the
individuals (or other units) followed in the trial were
assigned prospectively to one of two (or more)
alternative forms of health care using random allocation.”
The following information was extracted in duplicate by
two authors (NP, PSF) from each eligible protocol: title, first
author name, number of authors, country and geographic
region (i.e. Europe, Americas, Asia, Other) of first author,
details of registration, funding, number of trial sites, trial
design, funding type, conflict of interest, and data sharing.
Following the SPIRIT recommendation within the intro-
duction section the research context used to inform or
justify the trial was assessed in one of six ways [12]:
– randomised trial is the first to address the question
– updated systematic review was used to inform trial
design
– systematic review and new trials (published since
the systematic review was published) were used to
inform trial design
– previous systematic review was discussed but was
not used in trial design
– references to other randomised trials
– no references to other randomised trials or claim to
be the first trial
Data analysis
Data were independently extracted by two investigators
and entered on pre-piloted standardized forms for the
eligible protocols. Initial calibration was performed be-
tween the two researchers on ten articles. Disagreements
were resolved by discussion or, if necessary, with adjudica-
tion by a third reviewer and a consensus was reached for
all protocols. Descriptive statistics were undertaken and
data were tabulated with respect to selected protocol
characteristics with the use of STATA® version 14.1 soft-
ware (Stata Corporation, College Station, TX, USA).
Table 1 Search strategy for protocol selection
“protocol[ti] AND random*”
Filter for “randomised trials” and time range
1. randomised controlled trial [pt] OR controlled randomised trial [pt] OR
randomised [tiab] OR randomised [tiab] OR placebo [tiab] OR
randomly [tiab] OR trial [tiab]
2. protocol [tiab]
3. systematic review OR meta-analysis [ti] OR meta analysis [ti] OR review
[ti] OR Review [pt] OR Meta-Analysis [pt] OR Comment [pt] OR Letter
[pt] OR Editorial [pt] OR News [pt]
4. #1 AND #2 NOT #3
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Results
The PubMed search identified 411 records, 310 of which
were excluded as they did not satisfy the inclusion criteria
resulting in 101 protocols suitable for full data extraction
(Fig. 1). The Additional file 1 includes the raw data ex-
tracted. A variety of medical conditions were considered
in the selected protocols (Table 2). The majority of studies
were undertaken in multiple centres (84.2%). In terms of
geographic region, the highest percentage of studies was
carried out in Europe (54.5%; Table 2). Most proposed tri-
als were parallel-group (n = 74; 73.3%), while 9.9% (n = 10)
were cluster designs. The vast majority of studies reported
funding (94.1%) with non-industry funding in isolation in
82.2%. Conflict of interest statements were made in the
vast majority of protocols (n = 96; 95.0%), with the
majority having no conflicts to declare (n = 77; 76.2%). No
commitment to data sharing was made in the majority of
protocols (n = 93, 92.0%), 7% (n = 7) reported that data will
be available upon request and only one (1%) protocol
indicated the data repository.
In terms of citation of relevant research (Table 3), refer-
ence to a previous systematic review with additional rando-
mised trials was found in 9.9% (95% CI: 4.9, 17.5) (n = 10) of
protocols and without additional trials was alluded to in
30.7% (95% CI: 21.9, 40.7) (n = 31). A randomised controlled
trial was not cited in 10.9% (95% CI: 5.6, 18.7) (n = 11), while
in 8.9% (95% CI: 4.2, 16.2) (n = 9) of the protocols a
systematic review was cited but did not inform trial design.
Of the cited systematic reviews (n = 41), used to inform trial
design, 41.5% (n = 17) were Cochrane reviews.
From the 101 included protocols 89 of those were
published in journals endorsing the SPIRIT guidelines.
Discussion
The CONSORT statement has stipulated that findings
from a randomised trial should be placed in the context of
the “totality of the available evidence” [3]. Similarly, when
designing a new study it is important that the setting and
methodology is informed by previous research. This
cross-sectional analysis is the first to assess the citation of
high-level research, including both systematic reviews and
randomised controlled trials, in reports of published
protocols of planned randomised trials. Overall, 41% of
the protocols cited a systematic review or a randomised
trial that was used to inform trial design.
Previous analyses of reports of randomised trials have in-
dicated that systematic reviews are infrequently cited in re-
ports of randomised trials with sequential audits of trials
published in leading medical journals alluding to failure to
refer to systematic reviews in 24% of reports in 1997, 10%
in 2001, 33% in 2005, 46% in 2009 and 39% in 2012 [8–10].
This finding has arisen despite the pervasion of systematic
reviews with in excess of 5000 full Cochrane reviews now
published in the Cochrane Database of Systematic Reviews
[13] and several thousand more systematic reviews pub-
lished on an annual basis [14]. Our study indicates that trial
justification based on systematic reviews and randomised
trials at the protocol level is slightly higher compared to
published trials and this finding is encouraging, despite the
potential imprecision in obtaining these higher values
reflected by the wide confidence intervals. Reasons for this
are unclear at this stage but it could be speculated that the
utility of systematic reviews has improved over time, that a
greater onus on trial justification exists at the protocol stage
with funding agencies placing an emphasis on evidence of a
recent systematic review to justify further clinical research.
However, this is the first study to assess this and further
research may be required to confirm this pattern within
research protocols.
The SPIRIT guidelines were developed in response to
inadequate description of trial details such as outcomes and
interventions, but also due to unclear description of trial
methodology [7]. These shortcomings may prompt
protocol amendments, might hamper trial conduct and
can ultimately lead to inadequate reporting [15]. Moreover,
it is important that previous research is considered at the
design stages to avoid unnecessary duplication, to inform
trial design in order to maximize the yield from expensive
and lengthy randomised studies [1]. Where genuine uncer-
tainty concerning the effectiveness of an intervention is
lacking, undertaking such a trial is also considered
Fig. 1 RCT protocol selection flow diagram
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unethical. It is therefore recommended both within
the SPIRIT and CONSORT statements that relevant
randomised trials and systematic reviews are identified. It is
accepted, however, that compliance with established report-
ing and conduct guidelines is suboptimal throughout the
biomedical literature [16]. While meta-epidemiological
studies focusing on compliance with SPIRIT have not
yet been reported, the present investigation does report
some encouraging results.
A potential limitation of the present study is the possibil-
ity that there may not have been relevant trials or system-
atic reviews to cite at the time of the design of the new
trial. It is therefore possible that the prevalence of failure to
consider relevant research may be overstated slightly.
However, previous studies have attempted to identify
similar studies [11] but have found broadly similar rates of
Table 2 Distribution of demographic variables within the
protocols assessed (n = 101)
Characteristics of assessed protocols Total
N (101) %
Journal
Annals of Translational Medicine 1 1.0
BMC umbrella journals 23 22.7
BMJ Open 15 14.8
Clinical and Translational Allergy 1 1.0
Contemporary Clinical Trials 4 4.0
Danish Medical Journal 1 1.0
Implementation Science: IS 1 1.0
JAMA Surgery 1 1.0
JMIR Research Protocols 2 2.0
Journal of Advanced Nursing 3 3.0
Journal of Diabetes Science and Technology 1 1.0
Nutrients 1 1.0
Reproductive Health 1 1.0
Springer Plus 1 1.0
The Journal of Cardiovascular Nursing 1 1.0
Trials 44 43.5
Subject
Behavioural 49 48.5
Biological or vaccine 1 1.0
Dietary supplement 6 5.9
Drugs 18 17.8
Surgery or procedure 14 13.9
Other 13 12.9
No. centres (according to authors’ affiliations)
Multi-centre 85 84.2
Single-centre 16 15.8
Continent of authorship
America 19 18.8
Europe 55 54.5
Asia and other 27 26.7
No. sites (based on trial conduct)
Multiple 52 51.5
Single 49 48.5
Trial design
Parallel 74 73.3
Cluster 10 9.9
Non-inferiority 5 5.0
Superiority 2 2.0
Other (or mixed-type designs) 10 9.8
Type of funding
Non-industry 83 82.2
Table 3 Distribution of protocol characteristics in terms of
citation of relevant research (n = 101)
Protocol characteristics Total (n = 101)
N % 95% CI
Claims that randomised trial is the first to
address the question
18 17.8 10.9, 26.7
Contains an updated systematic review
used to inform trial design
31 30.7 21.9, 40.7
Contains systematic review and new trials
(published since the systematic review
was published) that were used to
inform trial design
10 9.9 4.9, 17.5
Previous systematic review discussed
but not used in trial design
9 8.9 4.2, 16.2
Contains references to other randomised trials 22 21.8 14.2, 31.1
Does not contain references to other
randomised trials or claim to be
the first trial
11 10.9 5.6, 18.7
Table 2 Distribution of demographic variables within the
protocols assessed (n = 101) (Continued)
Part industry 5 4.0
Industry 7 6.9
None/unknown 6 5.9
Conflict of interest
No 77 76.2
Yes 19 18.8
Not described 4 4.0
Unclear 1 1.0
Data sharing
Data upon request 7 7.0
Data stored in central repository 1 1.0
No information provided 93 92.0
Total 101 100.0
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isolated reports. Furthermore, the present study was limited
to a restricted time period and few sources. The search
strategy looked specifically for protocols in the title and
therefore it is possible that a number of trial protocols
might have been overlooked. However, the journals in-
cluded are likely to represent best practice in terms of
protocol design and reporting as most of them endorse
SPIRIT guidelines with the majority of trial protocols likely
remaining unpublished at this juncture. It is therefore likely
that the prevalence of failure to identify relevant related re-
search found in the present study represents a best-case
scenario. Finally, a limited number of pharmacological
studies were identified over the study period; further re-
search focusing on the protocol reporting characteristics
for these studies, in particular, would therefore be welcome.
Conclusions
A relatively high percentage of protocols of randomised
trials involves prior citation of either randomised trials,
systematic reviews or both. Overall, 41% of protocols
involved citation of a systematic review or a randomised
trial that was used to inform trial design.
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